Jazz Pharmaceuticals JAZZ Ziihera — Revenue from Contract with Customer, Excluding Assessed Tax
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's ziihera — revenue from contract with customer, excluding assessed tax.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's ziihera — revenue from contract with customer, excluding assessed tax?
- Jazz Pharmaceuticals (JAZZ) reported ziihera — revenue from contract with customer, excluding assessed tax of $13.3M in Q1 2026.
- How has Jazz Pharmaceuticals's ziihera — revenue from contract with customer, excluding assessed tax changed year-over-year?
- Jazz Pharmaceuticals's ziihera — revenue from contract with customer, excluding assessed tax increased by 565.0% year-over-year, from $2M to $13.3M.
- What does ziihera — revenue from contract with customer, excluding assessed tax mean?
- The total net sales revenue generated specifically from the Ziihera product line.
- How do you interpret ziihera — revenue from contract with customer, excluding assessed tax?
- An increase indicates successful market penetration, growing physician adoption, or expanded patient access for the therapy. A decrease may signal increased competition, loss of market share, or potential challenges in the product's lifecycle.
- How does ziihera — revenue from contract with customer, excluding assessed tax compare across companies?
- Comparable to product-specific net revenue disclosures in other biopharmaceutical companies, often benchmarked against similar oncology or specialty medicine launch trajectories.